Hypercholesterolemia is another disease that affects this elderly age group and has been associated with increased aggressiveness (Gleason 8-10) of prostate cancer.1 Statin therapy is common in patients predisposed to prostate cancer and has been associated with decreased incidence and aggressiveness of prostate cancer.2 This association was stronger with increased total dose, longer periods of treatment, and hydrophobic statin agents.3 Metastatic castration resistant prostate cancers (mCRPCs) are treated with androgen receptor blockers and androgen biosynthesis inhibitors. This evidence concerns the gene AR and prostate carcinoma.